P370 Quality of life of patients with inflammatory bowel diseases in remission on different forms of treatment

A. Kalaba*¹, M. Markovic², M. Jankovic¹, D. Zaric¹, S. Markovic¹, P. Svorcan¹

¹Clinical Center Zvezdara, Department of Gastroenterology, Belgrade, Serbia, ²Institute of Public Health of Belgrade, Health Promotion, Belgrade, Serbia

Background

Inflammatory bowel diseases (IBD), Crohn's disease and ulcerate colitis, are mostly common in young people, therefore the practical importance of researching on the quality of life of young people with chronic and lifelong illnesses is extremely high. It is indisputable that the application of biological therapy is a trend of treatment for these patients, but patients can also achieve satisfactory clinical and endoscopic remission with other therapeutic modalities. The goal of this paper was to evaluate and compare socio-demographic characteristics and quality of life of IBD patients on biological and immunomodulatory (IMD) therapy.

Methods

The cross-sectional study was conducted in period February–August 2018, at the Clinical Department of gastroenterology of Clinical Hospital Center Zvezdara, Belgrade, on 80 patients with UC and CD in remission (30 treated with biological therapy and 50 on IMD therapy). For the survey of socio-demographic characteristics and quality of life, Treatment Satisfaction Questionnaire for Medication-TSQM (Version 1.4) and Short Inflammatory Bowel Disease Questionnaire (SIBDQ) were used. Statistical analysis was performed using SPSS-17.0 and included methods of descriptive and analytical statistics (Student's t-test, χ² test, Fisher's exact test), with statistical significance set at p < 0.05, and confidence interval at 95% for all analysis.

Results

The average age of patients on biological therapy was 33.7 years (± 6.5), while average age of patients on other therapy modalities was 38.1 (± 12.7) years, which is a statistically significant difference (p = 0.045, t = −2.039). Although in patients on biological therapy, comparing the patients on IMD, proportion of males was larger, there was no statistically significant difference in gender representation among the groups (p = 0.203, χ² =1.617). Both groups reported small number of therapy negative effects, with no statistically significant difference (p = 0.10, χ² = 3.768), but the patient overall satisfaction was statistically significantly higher in those on biological therapy (p < 0.001, χ² =18.613). The average value of the estimated quality of life of patients on biological therapy was 54.99 out of the maximum 70 points, while in patients on other forms of treatment it was 32.2 (22.79 points less) (95% CI: 19.541–25.793), which is highly statistically significant (p < 0.01, t = 14.436).

Conclusion

The results of our survey indicate that patients with inflammatory bowel diseases on biological therapy express greater satisfaction and have a significantly higher quality of life in comparison to patients on IMD therapy.

Posted in: Poster presentations: Clinical: Therapy and observation (2019)